Spectral Medical says FDA 100-day PMA review for Toraymyxin does not require new clinical trial

PUBT · 2d ago
Spectral Medical says FDA 100-day PMA review for Toraymyxin does not require new clinical trial
  • Spectral Medical received an FDA deficiency letter during the 100-day PMA review for Toraymyxin.
  • FDA flagged additional analyses, testing, and clarifications needed to complete the review.
  • No additional clinical trial was requested as part of the FDA’s 100-day review.
  • Management does not expect the added work to materially change its overall regulatory timeline.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spectral Medical Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609110700PRIMZONEFULLFEED9824964) on September 11, 2026, and is solely responsible for the information contained therein.